
Powered by the Sharekhan 3R Research Philosophy



ESG I	NEW			
	SK RAT July 08, 20:			19.32
Low F	Risk _			
NEGL	LOW	MED	HIGH	SEVERE
0-10 10-20 20-30 30-40				40+
Source: Mo	orningstar			

Company details

Market cap:	Rs. 36,537 cr
52-week high/low:	Rs. 5,278/3,092
NSE volume: (No of shares)	3.8 lakh
BSE code:	533179
NSE code:	PERSISTENT
Free float: (No of shares)	5.3 cr

Shareholding (%)

Promoters	26.6
FII	24.8
DII	37.2
Others	11.4

5,500 5,000 4,500 4,500 3,500 2,500 2,500 2,500 2,500 2,500 2,500 2,500 2,500 2,500 2,500 2,500 2,500 2,500 2,500 3,000 2,500

Price performance

(%)	1m	3m	6m	12m
Absolute	-3.5	10.7	10.1	33.5
Relative to Sensex	-8.5	-1.0	0.1	13.8
Sharekhan Research, Bloomberg				

Persistent Systems Ltd

Decent Q1; Maintain Buy

IT & ITES				Share	ekha	in code: PERSISTENT	
Reco/View: Buy ↔		CM	P: Rs. 4,7	50	Price Target: Rs. 5,500	1	
	\uparrow	Upgrade	\leftrightarrow	Maintain	\downarrow	Downgrade	

Summary

- Persistent reported revenues of \$282.9 million, up 3%q-o-q/17.1% y-o-y in constant currency (CC) terms, nearly in line with our estimates of \$283.6 million
- EBIT margin fell ~50 bps q-o-q to 14.9% missing our estimates of 15.5%, as the tailwind of revenue growth was offset by higher SG&A costs, higher amortization costs, and doubtful debt provision.
- Order booking moderated to \$380.3 million in TCV, down ~10% q-o-q/3% y-o-y. Persistent would endeavour for aspirational quarterly growth of 3-5% in a good economy and 2-4% in a bad economy.
- Persistent Systems continues to deliver industry-leading revenue growth despite challenging macro
 environment on account of consistently decent order booking, strong contributions from top clients and
 broad-based demand across verticals. Hence, we maintain a Buy rating on Persistent Systems with
 revised PT of 5500. At the CMP, the stock trades at 30.1/24.4x its FY24/25E EPS.

Persistent reported revenue at \$282.9 million, up 3%q-o-q/17.1% y-o-y in constant currency nearly in line with our estimates of \$283.6 million. Revenue stood at Rs. 2321 crore, up 3% q-o-q/23.6% y-o-y. EBIT margins fell $^{\sim}50$ bps to 14.9% missing our estimates of 15.5% as the tailwind of revenue growth was offset by higher SG&A costs, higher amortization costs, and doubtful debt provision. Adjusted net profit stood at Rs 277.4 crore, up 10.3% q-o-q/ 31.1% y-o-y. There was a Rs. 48.6 one-off on account of \$-1bn revenue celebration. Order booking moderated at \$380.3 million in TCV terms, down ~10% q-o-q/3% y-o-y while deal ACV stood at \$271.9 million. The number of active clients increased by 8 to 369. The company added 1 client in \$20m-\$30m and 4 clients in \$5m-\$10m category. Headcount stood at 23,130, reflecting a net addition of 241 people during the quarter. LTM attrition moderated to 15.5% q-o-q, down 430 bps y-o-y. Utilisation improved 100bps to 78.3%q-o-q. Growth was led by BFSI, Software, Hitech & Emerging Industries, which grew 6.2%/3.3% q-o-q respectively. Order booking moderated as total TCVs stood at \$380.3 million, down 10%q-o-q/3%y-o-y. Book-to-bill ratio stood at 1.3x in Q1FY2024. New business TCVs stood at \$237.2 compared to \$250.3 million in Q4FY23. The company stated that they would endeavour for aspirational growth of 3-5% in a good economic and 2-4% in a bad economy with the aspiration 200-300 basis points margin improvement over the next 2 to 3 years. Persistent Systems continues to deliver industry-leading revenue growth despite challenging macro environment on account of consistently decent order booking, contributions from top clients and broad-based demand across verticals. Hence, we maintain a Buy rating on Persistent Systems with revised PT of 5,500. At CMP, the stock trades at 30.1/24.4x its FY24/25E EPS.

Keu positives

- LTM Attrition dropped to 15.5%, down 430 bps q-o-q
- Utilisation improved 100 bps g-o-g to 78.3%
- Revenue from the top client/top 5 grew 13 % and 8.5% q-o-q.

Key negatives

- Order booking moderated to \$380.3, down 10% q-o-q/3% y-o-y.
- Net additions were muted at 241 employees taking overall headcount to 23,130.

Management Commentary

- Company stated that they would endeavour for aspirational quarterly growth of 3-5% in a good economy and 2-4% in a bad economy.
- Management stated that the first priority is to ensure a healthy growth momentum, focusing on investing
 in sales, marketing, generative AI, and cloud data security. Optimizing margins in the next 2 to 3 quarters
 is not a primary concern, with the aspiration being 200 to 300 basis points improvement over the next 2 to
 3 years. Additionally, there is a significant under-utilization of freshers who have been with the company
 for 12-15 months, having undergone training and shadowing different programs.

Revision in estimates: We have fine-tuned our estimates for FY24/25E owing to macro-overhang.

Our Cal

Valuation – Decent Q1, Maintain Buy: Persistent delivered another quarter of industry-leading revenue growth on account of consistently decent order booking, strong contributions from top clients and broadbased demand across verticals. We expect 18%/25% Sales and PAT CAGR over FY23-25E. Hence, we maintain a Buy rating on Persistent Systems with a revised PT of 5,500. At CMP, the stock trades at 30.1/24.4x its FY24/25E EPS.

Key Risks

Rupee appreciation and/or adverse cross-currency movements. The contagion effect of banking crisis, macro headwinds and possible recession in the US are likely to moderate the pace of technology spends.

Valuation				Rs cr
Particulars	FY22	FY23	FY24E	FY25E
Revenue	5,710.7	8,350.6	9,860.1	11,622.0
OPM (%)	16.8	18.2	18.9	19.8
Adjusted PAT	690.4	950.7	1,213.0	1,495.7
% YoY growth	53.2	37.7	27.6	23.3
Adjusted EPS (Rs.)	90.3	127.2	157.7	194.5
P/E (x)	52.6	37.3	30.1	24.4
P/B (x)	10.8	9.2	7.7	6.5
EV/EBITDA (x)	39.3	24.9	19.5	15.3
RoNW (%)	22.4	25.9	28.0	29.0
RoCE (%)	26.0	27.8	30.4	32.8

Source: Company; Sharekhan estimates

July 21, 2023

Key Highlights

- Order bookings: Total TCVs stood at \$380.3 million, down 10%q-o-q/3%y-o-y. Book-to-bill ratio stood at 1.3x in Q1FY2024. New business TCVs stood at \$237.2 as compared to \$250.3 million in Q4FY23. Strong New Business ACV at \$168.3 million down 14% q-o-q/ up 3% y-o-y.
- Sequential growth across verticals: In terms of verticals growth was led by BFSI, Software, Hitech & Emerging Industries which grew 6.2%/3.3% q-o-q respectively while Health care & Lifesciences declined 2.7% q-o-q.
- **Growth across geographies:** In terms of geographies, growth was led by North America/India, which grew 4.8%/ 2.0% q-o-q respectively while Europe and ROW declined 4.9% /31.3% q-o-q.
- Strong sequential growth in top clients: Revenues from the top client grew 13 % q-o-q. Revenue from the top-5 clients grew by 8.5% q-o-q, while revenues from top-10 clients grew by 9% q-o-q. Revenue from the top-20 clients grew 8.4% q-o-q.
- Client addition: The company added 1 client in its \$20 million + revenue category on a sequential basis, while number of clients grew by four in \$5 million+ revenue category.
- **Utilisation improves, Attrition moderates:** Utilisation improved by 100 bps q-o-q to 78.3%. Attrition rate moderated by 430 bps to 15.5%. Net employee additions were 241 taking total headcount to 23,130. 800 freshers to join between August and December.
- Cash generation and DSO: Cash & investments stood at Rs. 1409.3 crore at the end of Q1FY24 versus Rs. 1,559.1 crore at the end of Q4FY23. DSO declined by one day sequentially to 67.


Results (Consolidated) Rs cr

Particulars	Q1FY24	Q1FY23	Q4FY23	YoY (%)	QoQ (%)
Revenues In USD (mn)	282.9	241.5	274.6	17.1	3.0
Revenues In INR	2,321.2	1,878.1	2,254.5	23.6	3.0
Direct Costs	1,527.8	1,243.3	1,489.4	22.9	2.6
SG&A	370.4	301.5	348.8	22.8	6.2
EBITDA	422.9	333.3	416.3	26.9	1.6
Depreciation & amortization	76.3	64.5	69.7	18.3	9.5
EBIT	346.6	268.8	346.6	29.0	0.0
Forex gain/(loss)	-6.4	4.2	-18.9	-253.3	-66.1
Other Income	15.5	8.9	12.9	73.4	19.8
PBT	355.7	281.9	340.6	26.2	4.4
Tax Provision	78.3	70.3	89.1	11.4	-12.1
PAT	277.4	211.6	251.5	31.1	10.3
Minority interest	0.0	0.0	0.0		
Net profit	228.8	211.6	251.5	8.1	-9.0
Exceptional items (IL&FS)	-48.6	0.0	0.0		
Adjusted net profit	277.4	211.6	251.5	31.1	10.3
EPS (Rs)	29.8	27.7	33.7	7.4	-11.6
Margin (%)					
EBITDA	18.2	17.7	18.5	47	-25
EBIT	14.9	14.3	15.4	62	-44
NPM	12.0	11.3	11.2	68	79
Tax rate	22.0	24.9	26.2	-292	-414

Source: Company, Sharekhan Research




USD revenue growth trend (y-o-y)




Source: Company, Sharekhan Research

EBIT margin trend (%)



Source: Company, Sharekhan Research

BFSI revenue growth trend (y-o-y)



Source: Company, Sharekhan Research


Healthcare and life sciences revenue growth trend (y-o-y)



Source: Company, Sharekhan Research


Sharekhan by BNP PARIBAS

Software and hi-tech revenue growth trend (y-o-y)




Source: Company, Sharekhan Research

Total deal TCV and new business ACV trend



Source: Company, Sharekhan Research

Top client (\$ mn) and growth (%)



Source: Company, Sharekhan Research



Outlook and Valuation

■ Sector view - Persisting multiple global headwinds turning outlook for FY24E uncertain

Owing to multiple global headwinds the outlook for FY24E looks uncertain, and the recovery could be gradual in the coming quarters. Hence concerns relating to macro headwinds are unlikely to abate anytime soon, thus restricting any material outperformance for Indian IT companies.

■ Company outlook - Well positioned to capture immense growth opportunity

As PSL is an early identifier of digital trends and has strong product development capabilities, we believe the company is well placed to capture a significant chunk of spends in digital technologies by clients going ahead. The management remains optimistic to deliver industry-leading revenue growth in FY2023 on account of broad-based demand across verticals, robust deal booking, new logo additions and incremental revenue from the acquired entities. We believe the company's leadership position in outsourced product development (OPD), elongated client relationships, and being an end-to-end service provider would help PSL to make the most of the opportunity.

■ Valuation - Decent Q1, Maintain Buy

Persistent delivered another quarter of industry-leading revenue growth on account of consistently decent order booking, strong contributions from top clients and broad-based demand across verticals. We expect 18%/25% Sales and PAT CAGR over FY23-25E. Hence, we maintain a Buy rating on Persistent Systems with a revised PT of 5,500. At the CMP, the stock trades at 30.1/24.4x its FY24/25E EPS.



Source: Sharekhan Research



About company

Incorporated in 1990, PSL is a global software company specialising in product and technology services. The company has proven expertise, strong presence in newer technologies, and strength to improve its IP base. PSL focuses on developing IoT products and platforms, as it sees significant traction from industrial machinery, SmartCity, healthcare, and smart agriculture verticals. PSL has been focusing on product development, establishing processes to build distributed agile teams, and partnering with the world's leading product companies to build software contributing across the entire product lifecycle. The company derives revenue from North America, Europe, and RoW.

Investment theme

Large corporates have been allocating higher budgets towards digital transformation initiatives and IT spends are moving from ISV to the enterprise model. PSL has restructured its business and aligned its sales resources to capitalise the benefits from clients' digital transformation journey. The alliance with IBM and investments in new-age technologies (IoT, Blockchain, artificial learning, and machine learning) are expected to help the company capture opportunities from these spends.

Key Risks

Rupee appreciation and/or adverse cross-currency movements. The contagion effect of banking crisis, macro headwinds and possible recession in the US are likely to moderate the pace of technology spends.

Additional Data

Key management personnel

Dr. Anand Deshpande	Founder, Chairman and MD
Sandeep Kalra	President: Technology Services
Sunil Sapre	Chief Financial Officer (CFO)
Mark Simpson	President, IBM Alliance

Source: Company

Top 10 shareholders

Sr. No.	Holder Name	Holding (%)
1	Kotak Mahindra Trustee Co	4.97
2	Kotak Mahindra Asset Management Co	4.4
3	Axis Asset Management Co Ltd/India	3.42
4	HDFC Asset Management Co Ltd	3.2
5	Motilal Oswal Asset Management Co	2.32
6	Vanguard Group Inc/The	2.14
7	PSPL ESOP Management Trust	2.05
8	Nippon Life India Asset Management	1.45
9	Fundrock Management Co Sa	1.36
10	Blackrock Inc	1.09

Source: Bloomberg

Sharekhan Limited, its analyst or dependant(s) of the analyst might be holding or having a position in the companies mentioned in the article.

Understanding the Sharekhan 3R Matrix

Right Sector	
Positive	Strong industry fundamentals (favorable demand-supply scenario, consistent industry growth), increasing investments, higher entry barrier, and favorable government policies
Neutral	Stagnancy in the industry growth due to macro factors and lower incremental investments by Government/private companies
Negative	Unable to recover from low in the stable economic environment, adverse government policies affecting the business fundamentals and global challenges (currency headwinds and unfavorable policies implemented by global industrial institutions) and any significant increase in commodity prices affecting profitability.
Right Quality	
Positive	Sector leader, Strong management bandwidth, Strong financial track-record, Healthy Balance sheet/cash flows, differentiated product/service portfolio and Good corporate governance.
Neutral	Macro slowdown affecting near term growth profile, Untoward events such as natural calamities resulting in near term uncertainty, Company specific events such as factory shutdown, lack of positive triggers/events in near term, raw material price movement turning unfavourable
Negative	Weakening growth trend led by led by external/internal factors, reshuffling of key management personal, questionable corporate governance, high commodity prices/weak realisation environment resulting in margin pressure and detoriating balance sheet
Right Valuation	
Positive	Strong earnings growth expectation and improving return ratios but valuations are trading at discount to industry leaders/historical average multiples, Expansion in valuation multiple due to expected outperformance amongst its peers and Industry up-cycle with conducive business environment.
Neutral	Trading at par to historical valuations and having limited scope of expansion in valuation multiples.
Negative	Trading at premium valuations but earnings outlook are weak; Emergence of roadblocks such as corporate governance issue, adverse government policies and bleak global macro environment etc warranting for lower than historical valuation multiple.

Source: Sharekhan Research



DISCLAIMER

This information/document has been prepared by Sharekhan Ltd. (SHAREKHAN) and is intended for use only by the person or entity to which it is addressed to. This Document may contain confidential and/or privileged material and is not for any type of circulation and any review, retransmission, or any other use is strictly prohibited. This information/ document is subject to changes without prior notice.

Recommendation in reports based on technical and derivatives analysis is based on studying charts of a stock's price movement, trading volume, outstanding positions, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. However, this would only apply for information/document focused on technical and derivatives research and shall not apply to reports/documents/information focused on fundamental research.

This information/document does not constitute an offer to sell or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Though disseminated to all customers who are due to receive the same, not all customers may receive this report at the same time. SHAREKHAN will not treat recipients as customers by virtue of their receiving this information/report.

The information contained herein is obtained from publicly available data or other sources believed to be reliable and SHAREKHAN has not independently verified the accuracy and completeness of the said data and hence it should not be relied upon as such. While we would endeavour to update the information herein on reasonable basis, SHAREKHAN, its subsidiaries and associated companies, their directors and employees ("SHAREKHAN and affiliates") are under no obligation to update or keep the information current. Also, there may be regulatory, compliance, or other reasons that may prevent SHAREKHAN and affiliates from doing so. This document is prepared for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Recipients of this report should also be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The user assumes the entire risk of any use made of this information. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved) and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. We do not undertake to advise you as to any change of our views. Affiliates of Sharekhan may have issued other recommendations/ reports that are inconsistent with and reach different conclusions from the information presented in this recommendations/report.

This information/recommendation/report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SHAREKHAN and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

The analyst certifies that the analyst might have dealt or traded directly or indirectly in securities of the company and that all the views expressed in this document accurately reflect his or her personal views about the subject company or companies and its or their securities and do not necessarily reflect those of SHAREKHAN. The analyst and SHAREKHAN further certifies that either he or his relatives or Sharekhan associates might have direct or indirect financial interest or might have actual or beneficial ownership of 1% or more in the securities of the company at the end of the month immediately preceding the date of publication of the research report. The analyst and SHAREKHAN encourages independence in research report/material preparation and strives to minimize conflict in preparation of research report. The analyst and SHAREKHAN does not have any material conflict of interest or has not served as officer, director or employee or engaged in market making activity of the company. The analyst and SHAREKHAN has not been a part of the team which has managed or co-managed the public offerings of the company, and no part of the analyst's compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this document. Sharekhan Ltd or its associates or analysts have not received any compensation for investment banking, merchant banking, brokerage services or any compensation or other benefits from the subject company or from third party in the past twelve months in connection with the research report.

Either SHAREKHAN or its affiliates or its directors or employees / representatives / clients or their relatives may have position(s), make market, act as principal or engage in transactions of purchase or sell of securities, from time to time or may be materially interested in any of the securities or related securities referred to in this report and they may have used the information set forth herein before publication. SHAREKHAN may from time to time solicit from, or perform investment banking, or other services for, any company mentioned herein. Without limiting any of the foregoing, in no event shall SHAREKHAN, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind.

Forward-looking statements (if any) are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not a guarantee of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements. Sharekhan/its affiliates undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader/investors are cautioned not to place undue reliance on forward-looking statements and use their independent judgement before taking any investment decision.

Investment in securities market are subject to market risks, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Client should read the Risk Disclosure Document issued by SEBI & relevant exchanges and the T&C on www.sharekhan.com

Registration and Contact Details: Name of Research Analyst - Sharekhan Limited, Research Analyst Regn No.: INH000006183. (CIN): - U99999MH1995PLC087498. Registered Office: The Ruby, 18th Floor, 29 Senapati Bapat Marg, Dadar (West), Mumbai – 400 028, Maharashtra, INDIA. Tel: 022-6115000.

Other registrations of Sharekhan Ltd.: SEBI Regn. Nos.: BSE / NSE / MSEI (CASH / F&O / CD) / MCX - Commodity: INZ000171337; DP: NSDL/CDSL-IN-DP-365-2018; PMS: INP000005786; Mutual Fund: ARN 20669.

Compliance Officer: Ms. Binkle Oza; Tel: 022-61169602; email id: complianceofficer@sharekhan.com

For any complaints/grievance, email us at igc@sharekhan.com or you may even call Customer Service desk on - 022-41523200/022-33054600